378 related articles for article (PubMed ID: 9825477)
1. Biochemical diagnosis of neuroendocrine GEP tumor.
Oberg K
Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
[TBL] [Abstract][Full Text] [Related]
2. Tumour markers in neuroendocrine tumours.
Oberg K; Janson ET; Eriksson B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
[TBL] [Abstract][Full Text] [Related]
3. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
4. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.
Rorstad O
J Surg Oncol; 2005 Mar; 89(3):151-60. PubMed ID: 15719376
[TBL] [Abstract][Full Text] [Related]
5. [Chromogranin A: a marker of neuroendocrine tumors].
D'Herbomez M; Gouze V
Ann Biol Clin (Paris); 2002; 60(6):641-6. PubMed ID: 12446227
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
7. Tumor markers in neuroendocrine tumors.
Eriksson B; Oberg K; Stridsberg M
Digestion; 2000; 62 Suppl 1():33-8. PubMed ID: 10940685
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
9. Biochemical testing for neuroendocrine tumors.
Vinik AI; Silva MP; Woltering EA; Go VL; Warner R; Caplin M
Pancreas; 2009 Nov; 38(8):876-89. PubMed ID: 19855234
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
Goebel SU; Serrano J; Yu F; Gibril F; Venzon DJ; Jensen RT
Cancer; 1999 Apr; 85(7):1470-83. PubMed ID: 10193936
[TBL] [Abstract][Full Text] [Related]
11. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours.
Tomassetti P; Migliori M; Lalli S; Campana D; Tomassetti V; Corinaldesi R
Ann Oncol; 2001; 12 Suppl 2():S95-9. PubMed ID: 11762360
[TBL] [Abstract][Full Text] [Related]
14. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas.
Abou-Saif A; Gibril F; Ojeaburu JV; Bashir S; Entsuah LK; Asgharian B; Jensen RT
Cancer; 2003 Jul; 98(2):249-61. PubMed ID: 12872342
[TBL] [Abstract][Full Text] [Related]
17. Bronchopulmonary carcinoid tumors--a significant diagnostic problem.
Kedra P; Jeleń M; Szkudlarek-Gruszczyńska T; Leśkow E
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():146-61. PubMed ID: 9337533
[TBL] [Abstract][Full Text] [Related]
18. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.
O'Toole D; Grossman A; Gross D; Delle Fave G; Barkmanova J; O'Connor J; Pape UF; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):194-202. PubMed ID: 19713711
[No Abstract] [Full Text] [Related]
19. State of the art and future prospects in the management of neuroendocrine tumors.
Oberg K
Q J Nucl Med; 2000 Mar; 44(1):3-12. PubMed ID: 10932597
[TBL] [Abstract][Full Text] [Related]
20. Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
Van Eeden S; Quaedvlieg PF; Taal BG; Offerhaus GJ; Lamers CB; Van Velthuysen ML
Hum Pathol; 2002 Nov; 33(11):1126-32. PubMed ID: 12454818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
